Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: A translational study

Translational Psychiatry

Volumn 7, Issue 4, 2017, Pages

  Jayaram Lindstrom N ^a   Guterstam, J ^a   Haggkvist J ^a   Ericson, M ^c   Malmlof T ^b   Schilstrom B ^b,c   Halldin, C ^a   Cervenka, S ^a   Saijo, T ^a   Nordstrom A L ^a   Franck, J ^a  

^a STOCKHOLM COUNTY COUNCIL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; NALTREXONE; PLACEBO; RACLOPRIDE C 11; CENTRAL STIMULANT AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NARCOTIC ANTAGONIST; RACLOPRIDE;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG USE; HUMAN; LIGAND BINDING; LONG TERM EXPOSURE; MALE; MICRODIALYSIS; NEUROMODULATION; NONHUMAN; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RAT; ANIMAL; CORPUS STRIATUM; DRUG EFFECTS; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SWEDEN; TRANSLATIONAL RESEARCH; WISTAR RAT;

ADULT; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; CROSS-OVER STUDIES; DOPAMINE; DOPAMINE AGENTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MICRODIALYSIS; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; SWEDEN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85038348662     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2017.79     Document Type: Article

References (51)

1. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005; 75: 406-433.
2. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49: 81-96.
3. Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003; 27: 615-621.
4. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. Amphetamineinduced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 2002; 27: 1027-1035.
5. Smith KS, Berridge KC, Aldridge JW. Disentangling pleasure from incentive salience and learning signals in brain reward circuitry. Proc Natl Acad Sci U S A 2011; 108: E255-E264.
6. Brauer LH, de Wit H. Subjective responses to d-Amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry 1996; 39: 26-32.
7. Jayaram-Lindström N, Wennberg P, Hurd YL, Franck J. Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 2004; 24: 665-669.
8. Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008; 33: 1856-1863.
9. Marks KR, Lile JA, Stoops WW, Rush CR. Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-Amphetamine in stimulant users. Psychopharmacology (Berl) 2014; 231: 2741-2750.
10. Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a Double-Blind, Placebo-Controlled Laboratory Study. Neuropsychopharmacology 2015; 40: 2347-2356.
11. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008; 165: 1442-1448.
12. Grant JE, Odlaug BL, Kim SW. A double-blind, placebo-controlled study of N-Acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol 2010; 20: 823-828.
13. Tiihonen J, Krupitsky E, Verbitskaya E, Blokhina E, Mamontova O, Föhr J et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 2012; 169: 531-536.
14. Häggkvist J, Lindholm S, Franck J. The effect of naltrexone on amphetamineinduced conditioned place preference and locomotor behaviour in the rat. Addict Biol 2009; 14: 260-269.
15. Häggkvist J, Lindholm S, Franck J. The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat. Behav Brain Res 2009 30; 197: 219-224.
16. Häggkvist J, Björkholm C, Steensland P, Lindholm S, Franck J, Schilström B. Naltrexone attenuates amphetamine-induced locomotor sensitization in the rat. Addict Biol 2011; 16: 20-29.
17. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994; 16: 255-262.
18. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-451.
19. Boileau I, Dagher A, Leyton M, Welfeld K, Booij L, Diksic M et al. Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine. J Neurosci 2007 11; 27: 3998-4003.
20. Cervenka S, Bäckman L, Cselényi Z, Halldin C, Farde L. Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. NeuroImage 2008; 40: 1287-1295.
21. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang D-R, Huang Y et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285-300.
22. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034-1057.
23. Joel D, Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000; 96: 451-474.
24. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage 1996; 4(3 Pt 1): 153-158.
25. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 4th edn, San Diego, CA, USA: Academic Press, 1998.
26. Schad CA, Justice JB, Holtzman SG. Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine. Eur J Pharmacol 1995; 275: 9-16.
27. Olive MF, Koenig HN, Nannini MA, Hodge CW. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci 2001; 21: RC184.
28. Xia Y, He L, Whistler JL, Hjelmstad GO. Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens. Neuropsychopharmacology 2008; 33: 892-900.
29. Schad CA, Justice JB, Holtzman SG. Endogenous opioids in dopaminergic cell body regions modulate amphetamine-induced increases in extracellular dopamine levels in the terminal regions. J Pharmacol Exp Ther 2002; 300: 932-938.
30. Guterstam J, Jayaram-Lindström N, Cervenka S, Frost JJ, Farde L, Halldin C et al. Effects of amphetamine on the human brain opioid system-A positron emission tomography study. Int J Neuropsychopharmacol 2013; 16: 763-769.
31. Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D et al. Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry 2012; 72: 371-377.
32. Mick I, Myers J, Stokes PRA, Erritzoe D, Colasanti A, Bowden-Jones H et al. Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. Int J Neuropsychopharmacol 2014; 17: 2069-2074.
33. Turchan J, Maj M, Przewlocka B, Przewlocki R. Effect of cocaine and amphetamine on biosynthesis of proenkephalin and prodynorphin in some regions of the rat limbic system. Pol J Pharmacol 2002; 54: 367-372.
34. Peciña M, Zubieta J-K. Molecular mechanisms of placebo responses in humans. Mol Psychiatry 2015; 20: 416-423.
35. Mitchell SH, Laurent CL, de Wit H. Interaction of expectancy and the pharmacological effects of d-Amphetamine: subjective effects and self-Administration. Psychopharmacology (Berl) 1996; 125: 371-378.
36. Courtney KE, Ghahremani DG, Ray LA. The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans. Neuropsychopharmacology 2016; 41: 2872-2881.
37. Volkow ND, Wang G-J, Telang F, Fowler JS, Logan J, Childress A-R et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006; 26: 6583-6588.
38. Wiskerke J, Schetters D, van Es IE, van Mourik Y, den Hollander BRO, Schoffelmeer ANM et al. μ-Opioid receptors in the nucleus accumbens shell region mediate the effects of amphetamine on inhibitory control but not impulsive choice. J Neurosci 2011; 31: 262-272.
39. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M et al. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006; 63: 1386-1395.
40. Olive MF, Anton B, Micevych P, Evans CJ, Maidment NT. Presynaptic versus postsynaptic localization of mu and delta opioid receptors in dorsal and ventral striatopallidal pathways. J Neurosci 1997; 17: 7471-7479.
41. Gerrits MAFM, Kuzmin AV, van Ree JM. Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone. Eur Neuropsychopharmacol 2005; 15: 297-303.
42. Unterwald EM, Horne-King J, Kreek MJ. Chronic cocaine alters brain mu opioid receptors. Brain Res 1992; 584: 314-318.
43. Unterwald EM, Rubenfeld JM, Kreek MJ. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 1994; 5: 1613-1616.
44. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 1996; 2: 1225-1229.
45. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino M et al. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol Psychiatry 2005; 57: 1573-1582.
46. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, Nelson R, Copersino ML et al. Brain muopioid receptor binding: relationship to relapse to cocaine use after monitored abstinence. Psychopharmacology (Berl) 2008; 200: 475-486.
47. Ghitza UE, Preston KL, Epstein DH, Kuwabara H, Endres CJ, Bencherif B et al. Brain mu-opioid receptor binding predicts treatment outcome in cocaine-Abusing outpatients. Biol Psychiatry 2010; 68: 697-703.
48. Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA et al. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-Amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology 2013; 38: 2427-2438.
49. Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-Alcohol dependence. Am J Addict 2009; 18: 356-362.
50. Daglish MRC, Williams TM, Wilson SJ, Taylor LG, Eap CB, Augsburger M et al. Brain dopamine response in human opioid addiction. Br J Psychiatry 2008; 193: 65-72.
51. Watson BJ, Taylor LG, Reid AG, Wilson SJ, Stokes PR, Brooks DJ et al. Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. Addict Biol 2014; 19: 1032-1040.